1.81 USD
+0.04 (+2.26%)
1.79 USD
-0.02 (-1.1%)
PLX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. PLX has an average financial health and profitability rating. PLX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PLX was profitable.
In the past year PLX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
PLX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 8.00%, PLX belongs to the best of the industry, outperforming 93.02% of the companies in the same industry.
The Return On Equity of PLX (12.57%) is better than 93.58% of its industry peers.
The Return On Invested Capital of PLX (12.68%) is better than 95.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROIC | 12.68% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 10.13%, PLX belongs to the top of the industry, outperforming 91.13% of the companies in the same industry.
With an excellent Operating Margin value of 13.28%, PLX belongs to the best of the industry, outperforming 92.64% of the companies in the same industry.
PLX has a Gross Margin of 57.53%. This is in the better half of the industry: PLX outperforms 77.92% of its industry peers.
PLX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
2. Health
2.1 Basic Checks
PLX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for PLX has been increased compared to 1 year ago.
PLX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PLX has an Altman-Z score of -2.06. This is a bad value and indicates that PLX is not financially healthy and even has some risk of bankruptcy.
PLX's Altman-Z score of -2.06 is in line compared to the rest of the industry. PLX outperforms 49.43% of its industry peers.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.06 |
ROIC/WACC1.4
WACC9.06%
2.3 Liquidity
A Current Ratio of 2.72 indicates that PLX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.72, PLX is doing worse than 68.87% of the companies in the same industry.
A Quick Ratio of 1.84 indicates that PLX should not have too much problems paying its short term obligations.
PLX has a worse Quick ratio (1.84) than 76.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
PLX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 153.85%, which is quite impressive.
The Revenue for PLX has decreased by -18.47% in the past year. This is quite bad
The Revenue has been decreasing by -0.48% on average over the past years.
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
3.2 Future
The Earnings Per Share is expected to grow by 85.63% on average over the next years. This is a very strong growth
Based on estimates for the next years, PLX will show a quite strong growth in Revenue. The Revenue will grow by 8.83% on average per year.
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue Next Year12.02%
Revenue Next 2Y14.31%
Revenue Next 3Y8.83%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 25.86, the valuation of PLX can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 93.58% of the companies listed in the same industry.
PLX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.57.
PLX is valuated reasonably with a Price/Forward Earnings ratio of 10.24.
Based on the Price/Forward Earnings ratio, PLX is valued cheaply inside the industry as 98.68% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of PLX to the average of the S&P500 Index (24.04), we can say PLX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.86 | ||
| Fwd PE | 10.24 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PLX is valued cheaply inside the industry as 97.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.74 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PLX's earnings are expected to grow with 85.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y142.73%
EPS Next 3Y85.63%
5. Dividend
5.1 Amount
No dividends for PLX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.81
+0.04 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners17.5%
Inst Owner Change16.94%
Ins Owners3.47%
Ins Owner Change0%
Market Cap145.56M
Revenue(TTM)53.40M
Net Income(TTM)6.28M
Analysts80
Price Target12.75 (604.42%)
Short Float %5.75%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.71%
PT rev (3m)-10.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-80.77%
EPS NY rev (3m)-80.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.86 | ||
| Fwd PE | 10.24 | ||
| P/S | 2.35 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.92 | ||
| P/tB | 2.92 | ||
| EV/EBITDA | 9.74 |
EPS(TTM)0.07
EY3.87%
EPS(NY)0.18
Fwd EY9.77%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.77
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROCE | 15.12% | ||
| ROIC | 12.68% | ||
| ROICexc | 32.84% | ||
| ROICexgc | 32.84% | ||
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% | ||
| FCFM | N/A |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 91.23% | ||
| Cap/Sales | 2.02% | ||
| Interest Coverage | 10.74 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z | -2.06 |
F-Score6
WACC9.06%
ROIC/WACC1.4
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
Revenue Next Year12.02%
Revenue Next 2Y14.31%
Revenue Next 3Y8.83%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A
PROTALIX BIOTHERAPEUTICS INC / PLX FAQ
What is the ChartMill fundamental rating of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to PLX.
What is the valuation status of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a valuation rating of 5 / 10 to PROTALIX BIOTHERAPEUTICS INC (PLX). This can be considered as Fairly Valued.
What is the profitability of PLX stock?
PROTALIX BIOTHERAPEUTICS INC (PLX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for PLX stock?
The Price/Earnings (PE) ratio for PROTALIX BIOTHERAPEUTICS INC (PLX) is 25.86 and the Price/Book (PB) ratio is 2.92.
Can you provide the expected EPS growth for PLX stock?
The Earnings per Share (EPS) of PROTALIX BIOTHERAPEUTICS INC (PLX) is expected to decline by -15.83% in the next year.